Foundayo cut sleep apnea events by 21.1 an hour in late-stage trial
Eli Lilly’s Foundayo cut apnea events by 21.1 per hour at 52 weeks in a late-stage trial; Lilly plans a year-end U.S. filing for moderate-to-severe OSA.
Topic
Glp 1
Topic
Glp 1
Hims & Hers Stock Jumps 4.7% on Eli Lilly GLP-1 Deal
Hims & Hers will sell Eli Lilly's Zepbound and Foundayo directly, dropping compounding. Shares rose 4.7% Friday but remain down 2…
ArrayPatch Closes €3.2M Seed Round for Polymer-Free Microneedle Patches
Cork-based ArrayPatch has closed a €3.2M seed round led by WakeUp Capital and Lakeside Capital to push its polymer-free GLP-1 mic…
Novo Nordisk lifts 2026 outlook as Wegovy pill gains traction
Novo Nordisk lifted 2026 sales and profit guidance to -2% to +2%. Third-quarter sales beat estimates, while the Wegovy pill poste…
Eli Lilly Raises 2026 Revenue Outlook to $91–92 Billion
Lilly raised 2026 revenue guidance to $91–92 billion after Q3 EPS of $7.48 beat estimates of $6.26, as Mounjaro sales jumped 65%…
Novo's CagriSema Delivers 25% Weight Loss in Women in Late-Stage Trial
Novo Nordisk says its experimental CagriSema injection achieved 25% weight loss in women in a late-stage analysis, topping the re…
Smaller Packages, Bigger Shift: Why Grocery Shelves Are Shrinking by 2035
NielsenIQ says the 2035 grocery store will run on mini cans and personal packs, as household size falls to 2.5 and 21% of homes i…
Walmart to Hand Out Ozempic and Mounjaro Free to Diabetic Staff
Walmart will hand Novo's Ozempic and Lilly's Mounjaro to Type 2 diabetes employees for free, plus inhalers and insulin, under a n…
McDonald's Bets $8.5 Billion on the Ozempic Era
McDonald's plans an $8.5 billion, decade-long overhaul with protein-heavy menu items and Google-built AI, as GLP-1 use hits 11% o…
Lilly Claims 61% of US GLP-1 Market as Novo Bets $23B Pipeline
Lilly holds 61% of the U.S. GLP-1 market and is gaining in pills and Medicare. Novo counters with a $23 billion pipeline bet, but…
Lilly Claims 70% of 700,000 New Medicare GLP-1 Seniors
Eli Lilly CEO Dave Ricks says 700,000 seniors started GLP-1s since July's Medicare coverage launch — and 70% of them are on Lilly…